AKT1 and triple-negative breast carcinoma: This is consistent with the demonstrated ability of niclosamide alone or in combination with cisplatin to effectively reverse EMT and inhibit the CSC -like phenotype of wild type and cisplatin-resistant triple negative breast cancer (TNBC) MDA-MB-231 cell line, by disrupting the aberrant activation of Akt, ERK, and Src signaling pathway26.